Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENACT: ENX-101 in Focal Epilepsy
NCT05481905Phase 2Withdrawn
- Sponsor
- Engrail Therapeutics
- Start
- Sep 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ENX-101 in focal epilepsy, sponsored by Engrail Therapeutics. Planned start Sep 2022; status: withdrawn.
02
Drugs
ENX-101
03
Conditions
focal epilepsy
Beyond the preview
Go deeper on NCT05481905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05481905.